Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen J Forman

Showing results (91-100 of 500) with videos related to

Pageof 50
Sort By:
Cancer Chemotherapy and Biological Response Modifiers|August 23, 2005
T-cell genetic modification for re-directed tumor recognitionLaurence J N Cooper, Michael Kalos, David DiGiusto, et al.
Experimental Hematology|June 26, 2007
Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cellsTontanai Numbenjapon, Lisa M Serrano, Wen-Chung Chang, et al.
Leukemia & Lymphoma|March 20, 2020
The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvementSalman Otoukesh, Jianying Zhang, Ryotaro Nakamura, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 23, 2010
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humansMichael C Jensen, Leslie Popplewell, Laurence J Cooper, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 6, 2016
Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell TransplantationIbrahim Aldoss, Ni-Chun Tsai, Marilyn L Slovak, et al.
Leukemia & Lymphoma|August 20, 2020
Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapyTamer A Othman, Jianying Zhang, Matthew Mei, et al.
Cancer|March 29, 2002
Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancyJun Wang, Lawrence M Weiss, Karen L Chang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 2, 2006
Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases--a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapyLinda M Griffith, Steven Z Pavletic, Alan Tyndall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoidesArturo Molina, Jasmine Zain, Daniel A Arber, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacityChy-Anh Tran, Luciana Burton, Diana Russom, et al.
Pageof 50

Showing results (91-100 of 500) with videos related to

Sort By:
Pageof 50
Cancer Chemotherapy and Biological Response Modifiers|August 23, 2005
T-cell genetic modification for re-directed tumor recognitionLaurence J N Cooper, Michael Kalos, David DiGiusto, et al.
Experimental Hematology|June 26, 2007
Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cellsTontanai Numbenjapon, Lisa M Serrano, Wen-Chung Chang, et al.
Leukemia & Lymphoma|March 20, 2020
The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvementSalman Otoukesh, Jianying Zhang, Ryotaro Nakamura, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 23, 2010
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humansMichael C Jensen, Leslie Popplewell, Laurence J Cooper, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 6, 2016
Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell TransplantationIbrahim Aldoss, Ni-Chun Tsai, Marilyn L Slovak, et al.
Leukemia & Lymphoma|August 20, 2020
Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapyTamer A Othman, Jianying Zhang, Matthew Mei, et al.
Cancer|March 29, 2002
Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancyJun Wang, Lawrence M Weiss, Karen L Chang, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 2, 2006
Target populations in allogeneic hematopoietic cell transplantation for autoimmune diseases--a workshop accompanying: cellular therapy for treatment of autoimmune diseases, basic science and clinical studies, including new developments in hematopoietic and mesenchymal stem cell therapyLinda M Griffith, Steven Z Pavletic, Alan Tyndall, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2005
Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoidesArturo Molina, Jasmine Zain, Daniel A Arber, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Manufacturing of large numbers of patient-specific T cells for adoptive immunotherapy: an approach to improving product safety, composition, and production capacityChy-Anh Tran, Luciana Burton, Diana Russom, et al.
Pageof 50